173 related articles for article (PubMed ID: 15973456)
1. A defined donor activating natural killer cell receptor genotype protects against leukemic relapse after related HLA-identical hematopoietic stem cell transplantation.
Verheyden S; Schots R; Duquet W; Demanet C
Leukemia; 2005 Aug; 19(8):1446-51. PubMed ID: 15973456
[TBL] [Abstract][Full Text] [Related]
2. Improved outcome in HLA-identical sibling hematopoietic stem-cell transplantation for acute myelogenous leukemia predicted by KIR and HLA genotypes.
Hsu KC; Keever-Taylor CA; Wilton A; Pinto C; Heller G; Arkun K; O'Reilly RJ; Horowitz MM; Dupont B
Blood; 2005 Jun; 105(12):4878-84. PubMed ID: 15731175
[TBL] [Abstract][Full Text] [Related]
3. Donor KIR Genes 2DL5A, 2DS1 and 3DS1 are associated with a reduced rate of leukemia relapse after HLA-identical sibling stem cell transplantation for acute myeloid leukemia but not other hematologic malignancies.
Stringaris K; Adams S; Uribe M; Eniafe R; Wu CO; Savani BN; Barrett AJ
Biol Blood Marrow Transplant; 2010 Sep; 16(9):1257-64. PubMed ID: 20302958
[TBL] [Abstract][Full Text] [Related]
4. Impact of Natural Killer Cell-Associated Factors on Acute Leukemia Outcomes after Haploidentical Hematopoietic Stem Cell Transplantation with αβ T Cell Depletion in a Pediatric Cohort.
Glushkova S; Shelikhova L; Voronin K; Pershin D; Vedmedskaya V; Muzalevskii Y; Kazachenok A; Kurnikova E; Radygina S; Ilushina M; Khismatullina R; Maschan A; Maschan M
Transplant Cell Ther; 2024 Apr; 30(4):435.e1-435.e12. PubMed ID: 38278183
[TBL] [Abstract][Full Text] [Related]
5. Risk assessment in haematopoietic stem cell transplantation: histocompatibility.
Petersdorf EW
Best Pract Res Clin Haematol; 2007 Jun; 20(2):155-70. PubMed ID: 17448954
[TBL] [Abstract][Full Text] [Related]
6. Deciphering the biology of KIR2DL3
David G; Willem C; Legrand N; Djaoud Z; Mérieau P; Walencik A; Guillaume T; Gagne K; Chevallier P; Retière C
Sci Rep; 2021 Aug; 11(1):15782. PubMed ID: 34349169
[TBL] [Abstract][Full Text] [Related]
7. Major Histocompatibility Complex and Hematopoietic Stem Cell Transplantation: Beyond the Classical HLA Polymorphism.
Bertaina A; Andreani M
Int J Mol Sci; 2018 Feb; 19(2):. PubMed ID: 29470425
[TBL] [Abstract][Full Text] [Related]
8. Use of natural killer cells as immunotherapy for leukaemia.
Grzywacz B; Miller JS; Verneris MR
Best Pract Res Clin Haematol; 2008 Sep; 21(3):467-83. PubMed ID: 18790450
[TBL] [Abstract][Full Text] [Related]
9. Development of natural killer cells from hematopoietic stem cells.
Yoon SR; Chung JW; Choi I
Mol Cells; 2007 Aug; 24(1):1-8. PubMed ID: 17846493
[TBL] [Abstract][Full Text] [Related]
10. A novel approach for quantification of KIR expression in healthy donors and pediatric recipients of hematopoietic SCTs.
Chen X; Knowles J; Barfield RC; Kasow KA; Madden R; Woodard P; Srivastava DK; Horwitz EM; Handgretinger R; Hale GA
Bone Marrow Transplant; 2009 Apr; 43(7):525-32. PubMed ID: 19029967
[TBL] [Abstract][Full Text] [Related]
11. Are changes in HLA Ags responsible for leukemia relapse after HLA-matched allogeneic hematopoietic SCT?
Hamdi A; Cao K; Poon LM; Aung F; Kornblau S; Fernandez Vina MA; Champlin RE; Ciurea SO
Bone Marrow Transplant; 2015 Mar; 50(3):411-3. PubMed ID: 25621795
[TBL] [Abstract][Full Text] [Related]
12. Can Graft vs. Leukemia Effect Be Uncoupled From Graft vs. Host Disease? An Examination of Proportions.
Krieger E; Toor AA
Front Immunol; 2020; 11():777. PubMed ID: 32425947
[No Abstract] [Full Text] [Related]
13. Clinical relevance of natural killer cells following hematopoietic stem cell transplantation.
Palmer JM; Rajasekaran K; Thakar MS; Malarkannan S
J Cancer; 2013; 4(1):25-35. PubMed ID: 23386902
[TBL] [Abstract][Full Text] [Related]
14. Poliovirus receptor-based chimeric antigen receptor T cells combined with NK-92 cells exert potent activity against glioblastoma.
Pan C; Zhai Y; Wang C; Liao Z; Wang D; Yu M; Wu F; Yin Y; Shi Z; Li G; Jiang T; Zhang W
J Natl Cancer Inst; 2024 Mar; 116(3):389-400. PubMed ID: 37944044
[TBL] [Abstract][Full Text] [Related]
15. Natural killer cells in antitumour adoptive cell immunotherapy.
Laskowski TJ; Biederstädt A; Rezvani K
Nat Rev Cancer; 2022 Oct; 22(10):557-575. PubMed ID: 35879429
[TBL] [Abstract][Full Text] [Related]
16. NK Cell-Based Immunotherapy and Therapeutic Perspective in Gliomas.
Pan C; Zhai Y; Li G; Jiang T; Zhang W
Front Oncol; 2021; 11():751183. PubMed ID: 34765554
[TBL] [Abstract][Full Text] [Related]
17. Dynamic mRNA expression of donor-derived activating KIR genes and their significant effects on clinical outcome after haematopoietic stem cell transplantation.
Li Y; Wang T; Hu X; Zhang H; Bao X; Wu D; He J
Clin Exp Immunol; 2021 Sep; 205(3):417-428. PubMed ID: 34085290
[TBL] [Abstract][Full Text] [Related]
18. Influence of KIR and NK Cell Reconstitution in the Outcomes of Hematopoietic Stem Cell Transplantation.
Gao F; Ye Y; Gao Y; Huang H; Zhao Y
Front Immunol; 2020; 11():2022. PubMed ID: 32983145
[TBL] [Abstract][Full Text] [Related]
19. Killer Immunoglobulin-Like Receptor-Ligand Interactions Predict Clinical Outcomes following Unrelated Donor Transplantations.
Krieger E; Sabo R; Moezzi S; Cain C; Roberts C; Kimball P; Chesney A; McCarty J; Keating A; Romee R; Wiedl C; Qayyum R; Toor A
Biol Blood Marrow Transplant; 2020 Apr; 26(4):672-682. PubMed ID: 31676338
[TBL] [Abstract][Full Text] [Related]
20. NK Cells in the Treatment of Hematological Malignancies.
Gonzalez-Rodriguez AP; Villa-Álvarez M; Sordo-Bahamonde C; Lorenzo-Herrero S; Gonzalez S
J Clin Med; 2019 Sep; 8(10):. PubMed ID: 31569769
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
